公开(公告)号：US20060134750A1

公开(公告)日：2006-06-22

申请号：US11298972

申请日：2005-12-09

申请人： Chih-Ping Liu ,  Lorelie Villarete

发明人： Chih-Ping Liu ,  Lorelie Villarete

IPC分类号： C12Q1/68 ,  C12P21/06

CPC分类号： A61K38/21

摘要： Methods of treating an autoimmune condition by administering IFNτ are described. IFNτ is administered orally at a dose sufficient to achieve obtain a desired clinical endpoint, such as a reduction in new contrast-enhanced brain lesions in multiple sclerosis patients.

摘要翻译： 描述了通过施用IFNtau治疗自身免疫病症的方法。 IFNtau以足以实现获得期望的临床终点的剂量口服给药，例如减少多发性硬化患者的新的对比度增强的脑损伤。

公开(公告)号：US06982081B2

公开(公告)日：2006-01-03

申请号：US09910406

申请日：2001-07-19

申请人： Yoshihiro Sokawa ,  Chih-Ping Liu

发明人： Yoshihiro Sokawa ,  Chih-Ping Liu

IPC分类号： A61K38/21

CPC分类号： A61K38/21

摘要： A method of monitoring treatment of HCV by oral administration of ovine IFN-τ is disclosed. The method includes measuring the blood levels of 2′,5′-oligoadenylate synthetase prior to and after such oral administration, and if necessary, adjusting the dose of IFN-τ until a measurable increase in blood 2′,5′-oligoadenylate synthetase level, relative to the level observed prior to administration, is observed. Also disclosed are oral-delivery compositions for use in treating HCV in an HCV-infected patient comprising ovine IFN-τ, in a dosage effective to stimulate bloodstream levels of 2′,5′-oligoadenylate synthetase.

公开(公告)号：US07695710B2

公开(公告)日：2010-04-13

申请号：US11728133

申请日：2007-03-23

申请人： Lorelie H. Villarete ,  Chih-Ping Liu

发明人： Lorelie H. Villarete ,  Chih-Ping Liu

IPC分类号： A61K38/21 ,  C07K14/00 ,  C08H11/02

CPC分类号： A61K38/21 ,  A61K38/212

摘要： Interferon-alpha (IFNα) analog proteins modified by chemical attachment of at least one hydrophilic polymer moiety, such as polyethylene glycol chain, are described for use in combination therapies with antiviral and/or antitumor agents. In one embodiment, the IFNα analog protein has an amino acid sequence that differs from a native human IFNα interferon-alpha by one or more amino acid residues in the N-terminal region, comprised of between about residues 1-27, inclusive, by one or more substitutions selected based on the amino acid residue at the corresponding position of a mature interferon-tau (IFNτ) protein. Methods of combination therapy are also described.

摘要翻译： 描述了通过化学连接至少一个亲水性聚合物部分（例如聚乙二醇链）修饰的干扰素-α（IFNα）类似物蛋白，用于与抗病毒和/或抗肿瘤剂的组合疗法。 在一个实施方案中，IFNα类似物蛋白具有不同于天然人IFNα干扰素-α的氨基酸序列，所述氨基酸序列在N末端区域中的一个或多个氨基酸残基（包括约残基1-27）和一个 或基于成熟干扰素-τ（IFNτ）蛋白的相应位置处的氨基酸残基选择的更多取代基。 还描述了联合治疗的方法。

公开(公告)号：US07431920B2

公开(公告)日：2008-10-07

申请号：US11112369

申请日：2005-04-22

申请人： Chih-Ping Liu ,  Lorelie H. Villarete ,  Stephen N. Kirnon

发明人： Chih-Ping Liu ,  Lorelie H. Villarete ,  Stephen N. Kirnon

IPC分类号： A61K38/21

CPC分类号： A61K38/21 ,  A61K38/00

摘要： A method for treating an IL-10 deficiency in a human subject is described, where a person having an IL-10 deficiency is identified and treated with interferon-tau (IFNτ) at a dose sufficient to increase the IL-10 level.

摘要翻译： 描述了用于治疗人受试者中IL-10缺乏症的方法，其中以足以增加IL-10水平的剂量鉴定并用干扰素-τ（IFNtau）处理具有IL-10缺乏症的人。

公开(公告)号：US07083782B2

公开(公告)日：2006-08-01

申请号：US10824710

申请日：2004-04-14

申请人： Chih-Ping Liu ,  Lorelie H. Villarete

发明人： Chih-Ping Liu ,  Lorelie H. Villarete

IPC分类号： A61K38/21

CPC分类号： A61K38/21 ,  Y02A50/463

摘要： Methods of treating an autoimmune condition, a viral infection, or a condition of cellular proliferation by administering IFNτ are described. More specifically, a method of up-regulating the IL-10 level in patients afflicted with an autoimmune condition, a viral infection, or a condition of cellular proliferation by administering IFNτ is described. IFNτ is administered at a dose sufficient to achieve an up-regulation of IL-10 in the blood, relative to the IL-10 level in the absence of IFNτ.

公开(公告)号：US07662370B2

公开(公告)日：2010-02-16

申请号：US11471788

申请日：2006-06-20

申请人： Lorelie H. Villarete ,  Chih-Ping Liu

发明人： Lorelie H. Villarete ,  Chih-Ping Liu

IPC分类号： A61K38/21 ,  C08H1/02 ,  C07K14/00

CPC分类号： C07K14/56 ,  A61K38/21 ,  A61K38/212 ,  A61K47/60

摘要： Interferon-alpha (IFNα) analog proteins modified by chemical attachment of at least one hydrophilic polymer moiety, such as polyethylene glycol chain, are described. In one embodiment, the IFNα analog protein has an amino acid sequence that differs from a native human IFNα interferon-alpha by one or more amino acid residues in the N-terminal region, comprised of between about residues 1-27, inclusive, by one or more substitutions selected based on the amino acid residue at the corresponding position of a mature interferon-tau (IFNτ) protein. Methods of treating viral diseases and other disorders with the polymer-modified IFNα analog protein are also described.

摘要翻译： 描述了通过化学连接至少一个亲水性聚合物部分如聚乙二醇链修饰的干扰素-α（IFNα）类似物蛋白质。 在一个实施方案中，IFNα类似物蛋白具有与天然人IFNα干扰素-α在N末端区域中的一个或多个氨基酸残基不同的氨基酸序列，其包含约1-27个（包含端点）和一个 或基于成熟干扰素-τ（IFNtau）蛋白的相应位置处的氨基酸残基选择的更多取代基。 还描述了用聚合物修饰的IFNα类似物蛋白治疗病毒性疾病和其它病症的方法。

公开(公告)号：US07232563B2

公开(公告)日：2007-06-19

申请号：US10218338

申请日：2002-08-12

申请人： Lorelie H. Villarete ,  Jackeline Campos ,  Wayne Li

发明人： Lorelie H. Villarete ,  Jackeline Campos ,  Wayne Li

IPC分类号： A61K38/21 ,  A61K39/00 ,  C07K14/00

CPC分类号： C07K14/56 ,  A61K38/00 ,  C07K14/555 ,  C07K2319/00

摘要： The present invention relates to hybrid interferon fusion proteins formed of an interferon-α protein where the C-terminal region of the interferon-α protein is replaced by a C-terminal region of interferon-τ. Also described are nucleic acid sequences encoding the interferon fusion proteins, expression vectors containing such sequences, and therapeutic applications of the interferon fusion proteins. The therapeutic applications include antiviral, anticellular proliferation, and anti-inflammatory applications. One advantage of the interferon fusion polypeptides of the present invention is that they have lower cytotoxic side effects when used to treat cells.

摘要翻译： 本发明涉及由干扰素-α蛋白形成的混合干扰素融合蛋白，其中干扰素-α蛋白的C-末端区被干扰素-τ的C-末端区域取代。 还描述了编码干扰素融合蛋白的核酸序列，含有这些序列的表达载体和干扰素融合蛋白的治疗应用。 治疗应用包括抗病毒，抗细胞增殖和抗炎应用。 本发明的干扰素融合多肽的一个优点是当用于治疗细胞时它们具有较低的细胞毒性副作用。

公开(公告)号：US20060257363A1

公开(公告)日：2006-11-16

申请号：US11410438

申请日：2006-04-24

申请人： Chih-Ping Liu ,  Lorelie Villarete ,  Stephen Kirnon

发明人： Chih-Ping Liu ,  Lorelie Villarete ,  Stephen Kirnon

IPC分类号： A61K38/21

CPC分类号： A61K38/21 ,  Y02A50/463

摘要： Methods of treatment using a high oral dose of an interferon are described. An interferon, such as interferon-alpha, interferon-beta, or interferon-tau, is administered to persons afflicted with an autoimmune condition, a viral infection, or a condition of cellular proliferation.

摘要翻译： 描述了使用高口服剂量的干扰素的治疗方法。 将干扰素（例如干扰素-α，干扰素-β或干扰素-τ）施用于患有自身免疫病症，病毒感染或细胞增殖的病症的人。

公开(公告)号：US07105154B2

公开(公告)日：2006-09-12

申请号：US10719472

申请日：2003-11-21

申请人： Yoshihiro Sokawa ,  Chih-Ping Liu

发明人： Yoshihiro Sokawa ,  Chih-Ping Liu

IPC分类号： A61K38/21

CPC分类号： A61K38/21 ,  A61K9/0095 ,  A61K47/26

摘要： A method for treating a condition responsive to interferon therapy in a human subject is described. The method includes orally administering interferon-tau to the intestinal tract in an amount effective to produce an increase in the subject's blood 2′, 5′-oligoadenylate synthetase (OAS) level, relative to the OAS level in the subject in the absence of interferon-tau.

摘要翻译： 描述了在人类受试者中治疗对干扰素治疗有效的病症的方法。 所述方法包括相对于不存在干扰素的受试者的OAS水平，有效地产生受试者的血液2'，5'-寡聚腺苷酸合成酶（OAS）水平的量向肠道口服施用干扰素tau au。

公开(公告)号：US20090035273A1

公开(公告)日：2009-02-05

申请号：US11893768

申请日：2007-08-16

申请人： Chih-Ping Liu

发明人： Chih-Ping Liu

IPC分类号： A61K38/21 ,  A61P31/12 ,  A61P35/00

CPC分类号： A61K38/212 ,  A61K38/215 ,  A61K2300/00

摘要： A method of treating conditions responsive to therapy with interferon-alpha or interferon-beta is provided, where the dose of interferon-alpha or interferon-beta is reduced and a dose of interferon-tau is additionally administered. The method results in efficacious therapy with a reduction in unwanted adverse events.

摘要翻译： 提供了一种治疗对干扰素α或干扰素-β治疗有反应的病症的方法，其中干扰素-α或干扰素-β的剂量减少，另外施用干扰素-τ的剂量。 该方法导致有效的治疗，减少不良不良事件。